Clinical Trials
0
0 active
Approvals
2
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
- Medunik USA has strengthened Pheburane® (sodium phenylbutyrate) coverage under Medicaid programs, with 19 states now offering preferred coverage and 29 states providing limited or no restrictions. - The expansion addresses treatment disparities for urea cycle disorders, which affect one in 35,000 Americans and can cause life-threatening ammonia buildup in the bloodstream. - Pheburane® is now reimbursed under commercial insurance plans reaching approximately 80% of the commercially insured US population, supported by comprehensive patient assistance programs. - The company's UNIK Support Program provides personalized clinical coordination, copay assistance with eligible patients paying as little as $0, and mail-order pharmacy services.
- Medunik USA announced that Siklos® (hydroxyurea) is now covered under Medicaid programs in 37 states, with 13 states including it on their Preferred Drug List and 24 states offering it with limited or no restrictions. - Siklos® is the only FDA-approved dissolvable formulation of hydroxyurea that reduces painful crises and blood transfusions for sickle cell patients aged 2 years and older, offering flexible dosing options. - The expanded coverage addresses a critical need for the nearly 100,000 Americans affected by sickle cell disease, which decreases life expectancy by 25 to 30 years and primarily affects individuals of African ancestry. - The medication carries a BOXED WARNING for low blood cell counts and cancer risks, requiring regular monitoring and careful patient management by healthcare providers.
